ORIC Pharmaceuticals announced equity inducement grants of 80,000 non-qualified stock options and 15,000 restricted stock units to a new non-executive employee hired in March 2026. The grants were approved by the Compensation Committee under Nasdaq Rule 5635(c)(4) and vest over time based on continued employment.

ORIC Pharmaceuticals (NASDAQ: ORIC) surged 3.94% during regular trading but plummeted 24.86% in after-hours trading despite releasing positive Phase 1b clinical data for its lead drug candidate rinzimetostat in combination with darolutamide for metastatic castration-resistant prostate cancer. The treatment showed an 84% radiographic progression-free survival rate with favorable safety outcomes, and the company selected a 400 mg once-daily dose for Phase 3 trials expected to begin in H1 2026. The sharp after-hours decline suggests investor caution around early-stage results or profit-taking.

The precision oncology market is projected to grow from $110 billion to $225.65 billion by 2032, driven by Big Pharma's race to acquire registration-ready assets ahead of a $170 billion patent cliff through 2030. Several biotech companies are advancing promising clinical programs: Oncolytics Biotech strengthened its leadership team for pelareorep development in gastrointestinal cancers; Nurix is executing pivotal studies for its BTK degrader bexobrutideg in chronic lymphocytic leukemia; Erasca reported early clinical data for its pan-RAS molecular glue ERAS-0015; Foghorn raised $50 million for its SMARCA4-targeting program; and ORIC presented strong Phase 1b data for rinzimetostat in prostate cancer.

ORIC Pharmaceuticals presented promising Phase 1b trial results for enozertinib, demonstrating strong systemic and CNS activity in NSCLC patients with EGFR exon 20 mutations, with high objective response rates and a competitive safety profile.

ORIC Pharmaceuticals presented promising Phase 1b trial results for enozertinib, a potential treatment for non-small cell lung cancer (NSCLC) with EGFR mutations, showing strong systemic and CNS activity with favorable safety profile.

ORIC Pharmaceuticals published research in Cancer Research detailing enozertinib, a highly selective brain-penetrant EGFR inhibitor targeting non-small cell lung cancer mutations, demonstrating potential for treating intracranial disease.

ORIC Pharmaceuticals, Inc. announced the grant of 39,100 non-qualified stock options and 6,500 restricted stock units to three new non-executive employees. The grants were made as inducements to employment in accordance with Nasdaq rules.

ORIC Pharmaceuticals, a clinical-stage oncology company, announced that it granted stock options and restricted stock units to two new non-executive employees as inducement awards. The grants were made under the company's 2022 Inducement Equity Incentive Plan.

The article discusses the promising developments in cancer research, including new therapies and innovative technologies, and highlights recent updates from several biotech companies working on cutting-edge cancer treatments.

ORIC Pharmaceuticals, a clinical-stage oncology company, announced granting stock options and restricted stock units to a new non-executive employee as an inducement to employment. The grants were made under the company's 2022 Inducement Equity Incentive Plan.

C4 Therapeutics, Inc. (C4T) has appointed Steve Hoerter, a veteran with over three decades of experience in oncology commercialization, to its Board of Directors. Hoerter's expertise in strategically advancing oncology programs is expected to guide C4T's plans to become a fully integrated biotechnology company.

ORIC Pharmaceuticals, a clinical-stage oncology company, announced granting stock options and restricted stock units to four new non-executive employees as inducement awards. The grants were made under the company's 2022 Inducement Equity Incentive Plan.